Search This Blog

Wednesday, September 5, 2018

Hospitals are the ones marking up drug prices: PhRMA


The blame game over drug prices is intensifying as drug industry group Pharmaceutical Research and Manufacturers of America (PhRMA) released a new report Wednesday about the role hospitals are playing in marking up the cost of prescriptions.
According to the report— produced by health consulting firm The Moran Company—hospitals mark up the cost of prescription drugs on average of nearly 500%. The report also says 17% of hospitals mark up the price of prescription drugs by at least 700%.
“Hospitals receive billions of dollars every year in negotiated and mandatory discounts from biopharmaceutical companies while simultaneously increasing the price of these medicines to insurers and patients,” said Stephen J. Ubl, president and chief executive officer of PhRMA in a statement. “In order to make medicines more affordable for patients, we must address the role hospital markups play in driving up medicine costs.”
PhRMA said average markups were likely much higher at hospitals participating in the 340B drug pricing program where medicines are acquired, on average, at a 50% discount.
Of course, policy experts have routinely said the best way to reduce high drug costs is to lower the list price of medications set by drug companies.

PhRMA has sought to spread the blame, launching ad campaigns to point to the contributions of other players including health systems, insurers and PBMs in the system after it became a natural target in the Trump administration’s focus on the problem of high prescription drug prices. As the Washington Post reported earlier this year, PhRMA started an industry war by seeking to explain to consumers role of pharmacy benefit managers while also calling them “middlemen” who were pocketing savings that might otherwise belong to patients.
They face an uphill battle. Healthcare costs, including drug prices, are expected weigh heavily in the upcoming midterms and a Kaiser Family Foundation poll released Wednesday found a growing share of the public who say drug companies are making too much profit is a “major reason” why healthcare costs have been rising. The same poll found a pretty even split with about 40% of the people polled said they thought Trump’s strategy of publicly shaming drug companies and asking them to cut prices will be effective while about 40% believe Trump will be able to deliver on his promise to cut the cost of prescription drugs.

In its analysis, Moran said it used Centers for Medicare and Medicaid Services 2016 cost report data in the Healthcare Provider Cost Report Information System. It examined all hospital-administered drugs to study the average mark up. Moran points out these are charged and not what hospitals are actually paid for the drugs.
This matters, they said, because hospitals are “routinely reimbursed as a percent of billed charges by commercial payers” driving up costs which can be passed along to patients, particularly those who are uninsured or do not have negotiated rates with the hospital.
See the report here:

Exact Sciences (EXAS) PT Raised to $100 at Cowen Following Pfizer Deal Deep-Dive


https://www.streetinsider.com/Analyst+Comments/Exact+Sciences+%28EXAS%29+PT+Raised+to+%24100+at+Cowen+Following+Pfizer+Deal+Deep-Dive/14575833.html

Some advise against routine testing for prostate cancer


Routine testing for prostate cancer is not recommended for most men because the benefit is small and uncertain and there are clear harms, say a panel of international experts in The BMJ today.
But they acknowledge that some men, such as those with a family history of , may be more likely to consider  and, for these men, discussions about possible harms and benefits with their doctor is essential.
Their advice is based on the latest evidence and is part of The BMJ‘s ‘Rapid Recommendations’ initiative—to produce rapid and trustworthy guidance based on new evidence to help doctors make better decisions with their patients.
The  (PSA) test is the only widely used test currently available to screen for prostate cancer. It is used in many countries, but remains controversial because it has increased the number of healthy men diagnosed with and treated unnecessarily for harmless tumours.
So an international panel, made up of clinicians, men at risk of prostate cancer, and research methodologists, carried out a detailed analysis of the latest evidence using the GRADE approach (a system used to assess the quality of evidence).
Based on a review (more than 700,000 men in clinical trials), which found that if screening reduces prostate cancer deaths at all, the effect is very small, the panel advises against offering routine PSA screening and says most men will decline screening because of the small and uncertain benefits and the clear harms.
Clinicians need not feel obligated to systematically raise the issue with all their patients, and should engage in shared decision making for those considering screening.
However, men at higher risk of prostate cancer death (for example, those with a family history of prostate cancer or of African descent) may be more likely to choose PSA screening after discussion of potential benefits and harms of testing with their doctor, authors concluded.
This view is supported in a linked editorial by Professor Martin Roland at the University of Cambridge and colleagues.
Both the panel and the editorialists welcome the UK government’s commitment to invest in  research, and point to recent advances and active surveillance “which have the potential to reduce the harms of testing.”
In the meantime, they say conversations with patients requesting a PSA test “should explore their reasons for requesting a test, and include evidence based discussions about possible harms and benefits of PSA testing, informed by the patient’s ethnicity and .”
More information: Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis, www.bmj.com/content/362/bmj.k3519
Rapid Recommendation: Prostate specific antigen (PSA) screening for prostate cancer: a clinical practice guideline, www.bmj.com/content/362/bmj.k3581
Editorial: What should doctors say to men asking for a PSA test? www.bmj.com/content/362/bmj.k3702

Study does not support wide preventive use of statins in healthy seniors


Statins are not associated with a reduction in cardiovascular disease (conditions affecting the heart and blood vessels) or death in healthy people aged over 75, finds a study published by The BMJ today.
The results of the study, led by the University Institute for Primary Care Research Jordi Gol (IDIAPJGol) and Girona Biomedical Research Institute (IDIBGI), do not support the widespread use of statins in old and very old people, but they do support treatment in selected people, such as those aged 75-84 years with type 2 diabetes, say the researchers.
Cardiovascular disease is the leading cause of death globally, especially for those aged 75 and over. Statin prescriptions to elderly patients have increased in recent decades, and trial evidence supports  treatment for people aged 75 years or older with existing (known as secondary prevention).
But evidence on the effects of statins for older people without heart disease (known as primary prevention) is lacking, particularly in those aged 85 years or older and those with diabetes.
So researchers based in Spain set out to assess whether statin treatment is associated with a reduction in cardiovascular disease and death in old (75-84 years) and very old (85 years and over) adults with and without type 2 diabetes.
Using data from the Catalan  system database (SIDIAP), they identified 46,864 people aged 75 years or more with no history ofcardiovascular disease between 2006 and 2015.
Participants were grouped into those with and without type 2 diabetes and as statin non-users or new users (anyone starting statins for the first time during the study enrollment period).
Primary care and hospital records were then used to track cases of CVD (including , angina, heart attack and stroke) and death from any cause (all cause mortality) over an average of 5.6 years.
In participants without diabetes,  was not associated with a reduction in CVD or all cause mortality in both old and very old age groups, even though the risk of CVD in both groups was higher than the risk thresholds proposed for statin use in guidelines.
In participants with diabetes, however, statins were associated with significantly reduced levels of CVD (24%) and all cause mortality (16%) in those aged 75-84 years. But this protective effect declined after age 85 and disappeared by age 90.
This was an observational study, so no firm conclusions can be drawn about cause and effect, and the authors cannot not rule out the possibility that some of their results may be due to unmeasured (confounding) factors.
But they point out that this was a high quality study with a large sample size, reflecting real life clinical conditions.
A such, they conclude that their results do not support the widespread use of statins in old and very old populations, but they do support treatment in those with type 2 diabetes younger than 85 years.
In a linked editorial, Aidan Ryan at University Hospital Southampton and colleagues, say the biggest challenge for clinicians is how to stratify risk among those aged more than 75 to inform shared decision making.
These observational findings should be tested further in randomised trials, they write. In the meantime, they say “patient preference remains the guiding principle while we wait for better evidence.”
More information: Statins for primary prevention of cardiovascular events and mortality in old and very old adults: retrospective cohort study, www.bmj.com/content/362/bmj.k3359
Editorial: Primary prevention with statins for older adults, www.bmj.com/content/362/bmj.k3695

Nurses at HCA hospitals say they could strike over pay, staffing, security


Registered nurses at 15 hospitals owned by the national chain, Hospital Corporation of America, have voted by an “overwhelming majority” to strike if contract negotiations are not resolved, a nurses union announced this week.
The hospitals include some in Florida and the Tampa Bay area, with the rest in Missouri, Kansas, Texas and Nevada.
The National Nurses Organizing Committee said its negotiators are working with HCA to ensure safe staffing ratios, raise wages and improve security for nurses.
In July, nurses at five local HCA hospitals picketed to raise awareness of the issues they face. Rosanne O’Malley, a registered nurse at the Medical Center of Trinity and chief nurse representative for the union, says safe staffing is the top issue.
“It’s very hard to do our jobs when we’re expected to take on too many patients,” said O’Malley, who has worked as a registered nurse for 31 years and a decade at Trinity. “Our company makes a huge profit every year, and we’d just like to see the people who do the work get some of that money. We would like to see annual raises for all nurses. The cost of living is going up and our wages are not going up at the same ratios.”
The union also is urging hospital management to address nurse turnover rates and invest in the recruitment and retention of nurses. O’Malley said the rise in the use of drugs and weapons is a growing concern for nurses treating unstable patients.
“There are unsafe conditions and it’s escalating,” she said.

Union officials say that HCA hospitals struggle with retaining staff, with more than 50 percent of nurses leaving their jobs within three years.
An HCA spokeswoman said it’s not uncommon for talk of strikes to bubble up during contract negotiations.
“We have bargaining dates scheduled later this month and we look forward to the union’s response to the proposal we provided to them back in July,” said JC Sadler, a spokeswoman for HCA’s West Florida division.
She touted the company’s “culture of compassion,” adding: “We want to assure our community that neither this — nor any other action — will ever come between us and our commitment to the high-quality care and services we offer our patients and this community on a daily basis.”
The strike authorization vote does not mean nurses will necessarily go on strike, union officials said. But it gives them the opportunity to do so if they feel the issues they face are not being addressed.
“Nurses are making it absolutely clear that we are ready to strike to ensure optimal care for our patients,” Jack Hood, a registered nurse in the ICU at Oak Hill Hospital in Brooksville, said in a statement.
“From Florida to Nevada, we are united in our commitment to negotiating a contract that provides solutions to the issues we are raising including turnover, recruitment and retention, and consistent compliance with staffing grids.”
The hospitals potentially affected by a strike employ nearly 7,000 nurses affiliated with the union. Four thousand of them live in Florida, union officials said.
HCA nurses at Northside Hospital in St. Petersburg, St. Petersburg General Hospital, Oak Hill Hospital in Brooksville and the Trinity Medical Center are being represented in the negotiations. HCA hospitals in Bradenton, Port Charlotte and Sarasota are affected as well.
Registered nurses affiliated with the National Nurses Organizing Committee have been in talks since contracts expired in May in Florida. No strike date has been set at this time. If a strike were to happen, participating nurses would give their hospital 10 days advance notice so management could prepare, union officials said.
The committee is affiliated with National Nurses United, one of the largest and fastest growing unions of registered nurses with 150,000 members.
Local HCA-employed nurses affiliated with National Nurses United have picketed for better wages several times in recent years. In 2015, they raised similar issues, calling for better wages and staffing levels. Local picketing also was reported in 2012.

Vegas Metro Chamber partners with Anthem on new association health plan


The Las Vegas Metro Chamber of Commerce announced Wednesday that it is partnering with Anthem Blue Cross Blue Shield to offer health plans to its members under a new Trump Administration rule that makes it easier for small businesses to collectively purchase insurance.
The chamber said in a statement that it has entered into an exclusive agreement for a two-year rate with Anthem to offer health insurance plans, some of which will be available as early as Oct. 1, to its members. The chamber will also offer dental, vision and life insurance benefits as part of its insurance package. According to the chamber, the plan will be the only one of its kind in Nevada to offer insurance to sole proprietors, small and medium-sized businesses and larger companies.
The announcement comes a little more than two months after the Department of Labor loosened rules on association health plans, exempting them from providing the essential health benefits required under the Affordable Care Act, eliminating restrictions based on geography and allowing companies in different industries in the same region to provide coverage together. At a June roundtable at the South Point Hotel & Casino, Trump touted that the new rule would give businesses “tremendous negotiating rights” and that the plans would soon cover “millions and millions of people.”
The chamber previously offered an association health plan that covered 20,000 people for nearly 30 years but stopped in 2014 after the Affordable Care Act began requiring all association health plans to cover what the federal health-care law deemed essential benefits, including prescription drug coverage and maternity care. Immediately after the rule was finalized in June, the chamber announced that it had been working for several months to develop a new Chamber Health Plan and that it would begin consulting with insurers to finalize a plan.
“We’ve listened to our members and brokers about what they need most,” said Las Vegas Metro Chamber President and CEO Mary Beth Sewald in a statement. “We are thrilled to announce this partnership with Anthem that combines robust health coverage with affordability and extremely competitive pricing.”
Anthem Blue Cross Blue Shield Nevada President Mike Murphy said in a statement that the insurance company “is committed to making high quality health care more accessible and affordable for consumers.”
The chamber released few specifics of the plan on Wednesday, saying only that the plans will offer “robust benefits and coverages, as well as very competitive pricing” and that the details of the new plan options would be released to insurance brokers and chamber members in September.
Association health plans have faced significant criticism for potentially offering fewer benefits than those sold on the health insurance exchange because they aren’t required to cover the same essential health benefits required under the ACA, though Sewald told The Nevada Independent in July that the chamber wanted to “do it right” and offer the best coverage it can to its members.
Separately, three other chambers of commerce — the Henderson Chamber of Commerce, Latin Chamber of Commerce and Boulder City Chamber of Commerce — announced last month that they were banding together as the Clark County Health Plan Association to offer plans to their members through UnitedHealthcare, though those plans are limited to small group employers with between one and 50 employees.

Amazon-Berkshire-JPM health JV led by Gawande has COO: Comcast’s Stoddard


AmazonBerkshire Hathaway and J.P. Morgan have found a chief operations officer to run their new health venture.
The group has hired Jack Stoddard, most recently general manager for digital health at Comcast. Previously, he was on the founding team of Accolade, a Comcast Ventures-backed start-up that helps workers manage their health benefits. He was also part of the executive team that created claims processing engine Optum, which was later acquired by UnitedHealth.
“We are very pleased to welcome Jack Stoddard to our team. He will serve as the chief operating officer of the organization going forward,” said a spokesperson.
Sources say that Stoddard’s first day is Tuesday.
Author and physician Atul Gawande officially started as CEO of the still-unnamed venture in July, where he kicked off the search for a team. The goal of the group is still murky, but J.P. Morgan’s Jamie Dimon recently told CNBC that the initiative will likely start small, in a similar manner to Amazon’s small-scale operation during its first few years.
The group has previously said it is looking to tackle the problem of rising health care costs for its combined 1.2 million workers. Many employers are finding that their costs are going up every year, but health outcomes are not improving.